Please login to the form below

Not currently logged in
Email:
Password:

Cardiovascular outcomes

This page shows the latest Cardiovascular outcomes news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets cardio outcomes claim for Praluent in EU

Sanofi gets cardio outcomes claim for Praluent in EU

Data stronger than rival's, could spark a fight back. The EU has approved a cardiovascular outcomes claim for Sanofi’s cholesterol-lowering antibody Praluent, finally setting it on par with ... Amgen has just announced a new four-year outcomes study

Latest news

  • Novartis in-licenses Akcea’s novel cardiovascular therapy Novartis in-licenses Akcea’s novel cardiovascular therapy

    The difficulty of developing and commercialising new cardiovascular treatments has been illustrated by two other Novartis drugs  - Entresto and canakinumab. ... Novartis plans to conduct a phase 3 cardiovascular outcomes trial, which will need to

  • Amgen, Servier start second phase 3 trial of heart failure hope Amgen, Servier start second phase 3 trial of heart failure hope

    GALACTIC-HF is a big cardiovascular outcomes study involving around 8, 000 with moderate to severe HFrEF and is intended to show that omecamtiv can extend the time to death or ... The results last year of the PIONEER-HF cardiovascular outcomes trial of

  • Trulicity’s ascent lifts Lilly Trulicity’s ascent lifts Lilly

    The once-weekly GLP-1 analogue is the company’s rising star, and was boosted in November when it unveiled compelling new cardiovascular outcomes data from its REWIND study.

  • Novo Nordisk preps for speedy oral GLP-1 drug filing Novo Nordisk preps for speedy oral GLP-1 drug filing

    Ozempic still has a long way to go before it catches Trulicity however, which is romping away in the diabetes market thanks in part to new cardiovascular outcomes data with sales

  • Pfizer takeover rumour ignites Amarin shares Pfizer takeover rumour ignites Amarin shares

    which found that the drug cut the risk of heart attacks and stroke by 25% in high-risk cardiovascular patients. ... The results rivalled the efficacy seen in cardiovascular outcomes trials for Amgen’s PCSK9 antibody Repatha (evolocumab), and

More from news
Approximately 1 fully matching, plus 104 partially matching documents found.

Latest appointments

  • Prof Sir Mike Richards joins Incisive Health as senior counsel Prof Sir Mike Richards joins Incisive Health as senior counsel

    In July 2012 he was appointed as Director for Reducing Premature Mortality on the NHS Commissioning Board (now NHS England), where he led the development of a cardiovascular outcomes strategy. ... These are vital attributes if the NHS is to navigate the

  • Teva's Mark Salyer joins Amarin Teva's Mark Salyer joins Amarin

    Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of results from the REDUCE-IT cardiovascular outcomes trial.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Conference research case study

    Our client had recently conducted a series of clinical trials with its breakthrough cardiovascular product, resulting in outcomes data which had the potential to give it a more competitive edge and ... Communication strategies and marketing messages were

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics